NICE (The National Institute for Health and Care Excellence) has released guidance recommending the use of Debrisoft to improve the treatment of acute and chronic wounds.
Debrisoft NICE guidance, released at the end of March 2014, supports the case that Debrisoft provides both multiple patient health benefits as well as significant cost savings for the NHS.
NICE’s evaluation of Debrisoft, which is used by nurses to manage acute and chronic patient wounds, found that the monofilament debridement pad:
The conclusion of the NICE guidance committee was that by using Debrisoft on appropriate wounds, these wounds would be ‘fully debrided more quickly, with fewer nurse visits needed compared with other debridement methods. In addition, the Debrisoft pad is convenient and easy to use, and is well tolerated by patients.’
Trudie Young, nurse and member of the expert panel working with NICE explains:
“The NICE guidance provides evidence that Debrisoft is a cost effective method of wound management, it is also convenient and easy to use.
Debrisoft is likely to completely debride appropriate wounds more quickly than some other methods.
Quicker debridement may give earlier visibility of the wound bed and therefore enable better management of the wound. Debrisoft is particularly effective on chronic, sloughy wounds with exudate and hyperkeratotic skin.
Dead tissue and offensive smelling wounds are very distressing to patients. So for me as a nurse, it is extremely rewarding to remove both quickly and painlessly with Debrisoft”.
Simon Barrett, Tissue Viability Specialist comments:
“Over time dressings evolve and improve on existing technology. It’s not often that something comes along which revolutionises practice like Debrisoft. Debrisoft gives the practitioner the opportunity to provide optimum care by improving how we treat the wound bed and care for skin”.
Alex Browning, Senior Product Manager at Activa Healthcare comments:
“NICE is the independent body responsible for driving improvement and excellence in the health and social care system. So we’re thrilled that Debrisoft has received such a positive acknowledgment from NICE. Debrisoft is already being used extensively across the UK by TVN’s, district nurses and practice nurses. We hope that this guidance will encourage more nurses to try Debrisoft in their everyday woundcare practice and experience first hand just how easy and effective Debrisoft is.”
Debridement (by Debrisoft) was effective in 93.4% (142/152) of the sessions. During the debridement procedure 45% of patients reported that they experienced no pain, 50.4% reported slight discomfort of short duration (mean 2 minutes) and 4.6% reported moderate pain of short duration (mean 2.4 minutes). No side effects after the procedure were reported by 56 out of 57 patients. No serious adverse events or adverse events were reported. Clinicians reported that the Debrisoft pad removed debris, slough, dried exudate and crusts efficiently, without damaging the fragile skin surrounding the wound. Photographic analysis confirmed this. Bahr et al. (2011) and Mustafi et al. (2011)
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for driving improvement and excellence in the health and social care system. It develops guidance, standards and information on high-quality health and social care. It also advises on ways to promote healthy living and prevent ill health.